Oxygen therapy developer Aviv Scientific completed a $40m series B round led by Danel while drug delivery system developer Credence raised almost as much.
Funding Medical services group Danel led a $40m series B round yesterday for Aviv Scientific, an Israel-based developer of oxygen therapy treatments to address age-related cognitive decline. The round included the deep technology-focused Deep Insight Fund and although Aviv has not revealed details of past funding, its technology stems from a partnership with Sagol Center,…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.